CN Bio Expands ADME Services with Computational Modeling Tools to Advance Drug Discovery
CN Bio has launched new PhysioMimix® computational modeling tools to strengthen ADME profiling, improve bioavailability predictions, and accelerate drug discovery workflows.
CN Bio, a global leader in organ-on-a-chip (OOC) systems, has unveiled new computational modeling tools designed to enhance bioavailability profiling and strengthen in vitro to in vivo extrapolation (IVIVE) for drug development.
The company’s new PhysioMimix® in silico capabilities integrate mathematical modeling with insights from microphysiological system (MPS) assays, offering drug developers deeper functional understanding of a compound’s absorption, distribution, metabolism, and excretion (ADME) profile.
Available through CN Bio’s Contract Research Services (CRS) or as standalone kits, these tools complement its proprietary dual-organ Gut/Liver bioavailability assay. The new computational models are fully compatible with physiologically based pharmacokinetic (PBPK) frameworks, enabling more accurate predictions of how compounds behave in the human body while extracting additional value from preclinical data.
Dr. Yassen Abbas, Lead Scientist at CN Bio, highlighted the regulatory momentum driving innovation:
“This year, the FDA made significant changes to phase out animal testing requirements, signaling a clear shift toward more relevant human approaches for preclinical safety and toxicity testing,” Abbas said. “By integrating advanced in silico modeling into our offering, we’re helping customers bridge the gap between in vitro data and in vivo translation, providing tools to design safer, more effective therapies.”
The updated CRS offering provides end-to-end support for clients, from study design to data interpretation. CN Bio’s team of MPS and computational modeling specialists collaborate closely with customers to ensure high-quality experimental outputs and clear, decision-ready insights to inform drug dosing and go/no-go decisions.
This launch follows CN Bio’s 2024 introduction of its bioavailability assay, marking another step toward modernizing preclinical workflows as the pharmaceutical industry moves away from traditional animal testing.
Author
BioFocus Newsroom